

REMARKS

Claims 1-109 are pending in the application. Claims 78, 79, 84-91 and 98-103 have been canceled without prejudice. Claim 7 has been amended to correct a typographic error. Accordingly, the word "[t]he" has been inserted at the start of the claim.

REJECTION OF CLAIMS UNDER 35 U.S.C. 112 FIRST PARAGRAPH

The Examiner has rejected Claims 78-79, 84-91 and 98-103 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. To advance the prosecution of this case, Applicant has canceled these claims without prejudice.

REJECTION OF CLAIMS UNDER 35 U.S.C. 112 SECOND PARAGRAPH

The Examiner has also rejected Claims 78, 100 and 102 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Again, to advance the prosecution of this case, Applicant has canceled these claims without prejudice.

In view of the amendment and remarks contained herein, Applicants submit the application is in condition for allowance.

Conclusion

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. USHMR2021US PCT